Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E9.83 EPS (ttm)23.33 Insider Own0.10% Shs Outstand195.24M Perf Week1.35%
Market Cap44.76B Forward P/E7.47 EPS next Y30.68 Insider Trans- Shs Float189.98M Perf Month0.92%
Income4.69B PEG1.50 EPS next Q7.47 Inst Own93.10% Short Float2.09% Perf Quarter-31.12%
Sales13.81B P/S3.24 EPS this Y24.50% Inst Trans-1.80% Short Ratio1.60 Perf Half Y-28.14%
Book/sh70.35 P/B3.26 EPS next Y3.48% ROA18.40% Target Price261.62 Perf Year-18.55%
Cash/sh20.02 P/C11.45 EPS next 5Y6.56% ROE35.30% 52W Range216.12 - 388.67 Perf YTD-23.81%
Dividend- P/FCF7.51 EPS past 5Y22.70% ROI23.60% 52W High-41.01% Beta0.97
Dividend %- Quick Ratio2.60 Sales past 5Y14.20% Gross Margin85.70% 52W Low6.09% ATR5.60
Employees7800 Current Ratio2.80 Sales Q/Q11.50% Oper. Margin42.40% RSI (14)36.17 Volatility1.93% 2.56%
OptionableYes Debt/Eq0.00 EPS Q/Q29.10% Profit Margin33.80% Rel Volume0.76 Prev Close230.87
ShortableYes LT Debt/Eq0.43 EarningsApr 24 BMO Payout0.00% Avg Volume2.49M Price229.28
Recom2.80 SMA20-0.03% SMA50-7.70% SMA200-25.73% Volume1,888,118 Change-0.69%
Apr-10-19Resumed Raymond James Mkt Perform
Mar-25-19Reiterated H.C. Wainwright Buy $363 → $300
Mar-22-19Reiterated BMO Capital Markets Market Perform $322 → $250
Mar-22-19Downgrade UBS Buy → Neutral $395 → $242
Mar-22-19Downgrade Morgan Stanley Overweight → Underweight $401 → $210
Mar-22-19Downgrade Canaccord Genuity Buy → Hold $396 → $275
Mar-21-19Reiterated Guggenheim Neutral $325
Mar-21-19Downgrade William Blair Outperform → Mkt Perform
Mar-21-19Downgrade Wells Fargo Outperform → Market Perform
Mar-21-19Downgrade Mizuho Buy → Neutral
Mar-21-19Downgrade JP Morgan Overweight → Neutral
Mar-21-19Downgrade Goldman Buy → Neutral
Mar-21-19Downgrade Citigroup Buy → Neutral
Mar-21-19Downgrade BofA/Merrill Buy → Neutral
Mar-21-19Downgrade Atlantic Equities Overweight → Neutral
Feb-21-19Downgrade Stifel Buy → Hold $397 → $346
Dec-21-18Initiated BTIG Research Buy
Oct-19-18Downgrade Bernstein Outperform → Mkt Perform
Oct-08-18Reiterated Citigroup Buy $483 → $470
Oct-01-18Resumed Cantor Fitzgerald Overweight $400
May-17-19 05:17PM  Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid Zacks
May-16-19 02:54PM  Wayfair cracks Fortune 500 list, joins 15 other Mass. companies American City Business Journals
05:00AM  Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks
May-15-19 07:50AM  Stocks making the biggest moves premarket: Alibaba, Zillow Group, Biogen, McDonald's, Beyond Meat & more CNBC
07:50AM  The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi Benzinga
07:42AM  5 Low Price-to-Book Value Stocks for Great Returns Zacks
May-14-19 08:05PM  NHS England, Biogen reach deal on pricey drug for deadly disorder Reuters
07:07PM  NHS England, Biogen reach deal on pricey drug for deadly disorder Reuters
07:02PM  Biogens SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy GlobeNewswire
03:51PM  Ionis Pharmaceuticals Is 40% of the Way There Motley Fool
May-13-19 04:24PM  Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store? Zacks
08:00AM  Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease PR Newswire
May-10-19 10:51AM  PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y Zacks
08:40AM  Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease PR Newswire
May-09-19 12:32PM  Stock Buybacks Surge Kiplinger
May-08-19 04:49PM  Parnassus Endeavor Fund Buys AbbVie, Boosts Biogen
01:44PM  Jeff Auxier Comments on Biogen
01:18PM  Jeff Auxier's 1st Quarter Auxier Focus Fund Shareholder Letter
May-07-19 04:57PM  Biotech ETFs in Focus on String of Q1 Earnings Beats Zacks
04:33PM  This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen Investor's Business Daily
07:30AM  Data at AAN Demonstrate Biogens Leadership and Commitment to Innovation in MS GlobeNewswire
May-06-19 04:53PM  Jerome Dodson Comments on Biogen
11:20AM  Weekly CEO Buys Highlight
07:44AM  Notable Insider Buys This Past Week: ADM, Biogen, Grubhub and More Benzinga
07:30AM  Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen) GlobeNewswire
07:00AM  Biogen Stock Is Near a Multiyear Low. The CEO and a Hedge Fund Bought Millions.
May-05-19 03:27PM  Top Insider Buys Highlight for the Week of May 3
May-02-19 01:21PM  These 6 biotech stocks are promising takeover targets MarketWatch
11:18AM  The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex Zacks
11:05AM  Betting Against Biogen Stock Might Be Fashionable, but Its a Mistake, Analyst Says
10:24AM  What Do Analysts Think About Biogen Inc.'s (NASDAQ:BIIB) Future? Simply Wall St.
08:16AM  The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data Benzinga
May-01-19 04:30PM  Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) GlobeNewswire
01:36PM  David Carlson Buys 2 Stocks, Sells 1 in 1st Quarter
11:52AM  Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates Zacks
09:26AM  What's in the Cards for Sunesis (SNSS) This Earnings Season? Zacks
07:30AM  Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases GlobeNewswire
Apr-30-19 12:46PM  3 Tech Stocks for Growth Investors to Buy Right Now Zacks
11:44AM  Biogen Is 3 Adding Directors. Investors Might Question Whether Thats Bold Enough.
10:54AM  10 Workhorse Health Care Stocks That Never Break a Sweat Kiplinger
10:53AM  The 10 Best Health Care Stocks to Buy for 2019 Kiplinger
07:33AM  Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy GlobeNewswire
Apr-29-19 07:30AM  Biogen Announces Three New Nominees for Election to Board of Directors GlobeNewswire
Apr-28-19 11:19AM  Biogen says it will not give up on Alzheimers after failed trials MarketWatch
Apr-27-19 11:54AM  Cramer's Takeaways for Ford, Chevron, Alibaba, Biogen, Visa
Apr-26-19 04:21PM  Is This Highly-Anticipated Gene Therapy in Trouble? Motley Fool
03:58PM  Alkermes Looks Ahead to Growth Motley Fool
07:26AM  Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1 Zacks
06:10AM  Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals
Apr-25-19 04:37PM  Jerome Dodson's 1st Quarter Parnassus Endeavor Fund Commentary
03:47PM  Biogen Looks to 23 Clinical Programs for Growth Motley Fool
03:10PM  Bitcoin and Biogen among the second round 2019 Stock Draft picks CNBC Videos
02:46PM  Here is who's competing in the 2019 Stock Draft, the rules and the first pick CNBC Videos
12:18PM  IPO Cortexyme Hopes to Succeed in Alzheimer's Where Giants like Biogen Have Failed
10:36AM  Edited Transcript of BIIB earnings conference call or presentation 24-Apr-19 12:00pm GMT Thomson Reuters StreetEvents
10:04AM  AbbVie says Humira rivals from Biogen, Amgen most aggressive so far Reuters
10:01AM  AbbVie says Humira rivals from Biogen, Amgen most aggressive so far Reuters
Apr-24-19 04:18PM  Biogen Won't Disavow Its Alzheimer's Goal So What's Next For Growth? Investor's Business Daily
03:44PM  Biogen Inc (BIIB) Q1 2019 Earnings Call Transcript Motley Fool
12:28PM  Biogen Earnings: BIIB Stock Slips Despite Q1 Beat InvestorPlace
12:25PM  Stocks making the biggest moves midday: AT&T, Domino's Pizza, eBay & more CNBC
11:40AM  Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales Zacks
11:38AM  Biogen dips as strategy post Alzheimer's setback fails to impress Reuters
11:22AM  Biogen Stays the Wrong Course After a Key Drug Failure Bloomberg
10:24AM  You can find plenty of solid stock bargains in this years worst-performing sector, analysts say MarketWatch
10:04AM  Biogen Stock Slips Because Strong Earnings Cant Make Up for Its Failed Alzheimer Drug
10:04AM  Biogen Shares Fall After Drugmaker Meets Earnings Estimates
08:36AM  Biogen (BIIB) Q1 Earnings & Sales Beat Estimates Zacks
07:33AM  Biogen stock up 1.8% in premarket trade after revenue beat MarketWatch
07:15AM  Biogen beats first-quarter profit estimates on Spinraza strength Reuters
06:51AM  Biogen first-quarter profit rises 20 percent on Spinraza strength Reuters
06:36AM  Biogen first-quarter profit rises 20 percent Reuters
02:33AM  Biogen Earnings, Revenue Beat in Q1
Apr-23-19 10:53PM  Biogen promises to plug pipeline gap after Alzheimers failure Financial Times
10:11AM  Health-care earnings: Medicare for all looms large MarketWatch
09:27AM  What's in Store for Celgene Corporation (CELG) Q1 Earnings? Zacks
08:15AM  Biogen Reports Earnings Tomorrow. Heres What to Expect.
Apr-22-19 05:00PM  Better Buy: Biogen vs. AbbVie Motley Fool
10:17AM  Biogen (BIIB) to Report Q1 Earnings: What's in the Cards? Zacks
08:30AM  Will Bristol-Myers (BMY) Disappoint This Earnings Season? Zacks
07:00AM  Patients living with Spinal Muscular Atrophy (SMA) in the province of Saskatchewan gain access to SPINRAZA (nusinersen) CNW Group
Apr-18-19 10:29AM  Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs Zacks
Apr-17-19 02:34PM  Here's Why Ionis Pharmaceuticals Slumped Today Motley Fool
01:45PM  2 Beaten Down Bluechips: Are They Buys? Motley Fool
10:31AM  Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Apr-15-19 05:45PM  Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
03:00PM  Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's American City Business Journals
06:58AM  Goldman Sachs's 20 best stocks to invest in now Yahoo Finance
Apr-14-19 09:16AM  Better Buy: Gilead Sciences vs. Biogen Motley Fool
Apr-12-19 07:30AM  Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference GlobeNewswire
Apr-11-19 06:33AM  Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock InvestorPlace
12:00AM  An AI Firm Wants to Predict Costly Pharma Flops Bloomberg
Apr-10-19 09:59AM  Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds Benzinga
Apr-09-19 05:45PM  Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
05:01PM  6 Predictable Guru Stocks
Apr-07-19 11:59PM  Sarissa Capital Management Hires New President Insider Monkey
Apr-06-19 06:13PM  Should Biogen Investors Be Extra Nervous Right Now? Motley Fool
Apr-04-19 03:54PM  Here's What Biogen Inc.'s (NASDAQ:BIIB) P/E Ratio Is Telling Us Simply Wall St.
02:49PM  1 Biotech That Biogen Should Buy ... but Probably Won't Motley Fool
01:28PM  Buy Biogen on the dip? What about AMC on the streaming wars? The viewers #AskHalftime CNBC Videos
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,480022,487May 06 04:20 PM
DENNER ALEXANDER JDirectorMay 02Buy231.2438,0008,787,120643,000May 02 05:06 PM
DENNER ALEXANDER JDirectorMay 01Buy229.4630,0006,883,800605,000May 02 05:06 PM
Vounatsos MichelChief Executive OfficerMay 01Buy231.484,3511,007,16921,007May 02 04:30 PM
DENNER ALEXANDER JDirectorApr 30Buy229.2550,34211,540,904575,000May 02 05:06 PM
PANGIA ROBERT WDirectorMar 18Option Exercise52.226,114319,27324,701Mar 19 04:08 PM
PANGIA ROBERT WDirectorMar 18Sale328.556,1142,008,75518,587Mar 19 04:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0056807,488Mar 05 04:17 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 22Option Exercise38.518,058310,28536,085Feb 26 05:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,663011,148Feb 26 05:07 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,269018,914Feb 20 06:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,318010,071Feb 20 06:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,44807,968Feb 20 06:07 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,68508,526Feb 20 05:54 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 15Option Exercise0.001,685028,776Feb 20 05:53 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.006,899016,267Feb 14 06:33 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.004,64309,452Feb 14 06:29 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,06207,059Feb 14 06:17 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,83602,561Feb 14 06:10 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 12Option Exercise0.003,82707,639Feb 14 06:07 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 12Option Exercise0.003,268027,710Feb 14 06:04 PM
DENNER ALEXANDER JDirectorFeb 01Buy328.457,0002,299,163524,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 31Buy330.5225,8008,527,393517,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 30Buy324.8630,0009,745,851491,858Feb 01 04:19 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,33101,331Jan 04 04:17 PM
Guindo ChirfiEVP Glob. Mkt Acc & Cust InnovDec 01Option Exercise0.0060202,721Dec 04 08:21 PM
Ehlers Michael DEVP, Research and DevelopmentSep 26Sale350.001,000350,0004,281Sep 27 04:16 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0026201,122Aug 03 04:14 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,38405,897Jun 05 04:31 PM